{"filings":[{"id":807998,"accession_number":"0001193125-26-253784","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-06-02T21:00:32+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shattuck Labs shareholders approve equity plan amendment adding 1.69M shares, extend term to 2036","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Shareholders approved amendment to 2020 Equity Incentive Plan, increasing share reserve by 1,691,082 shares and extending term to March 23, 2036.","Plan includes automatic annual increase of 4% of outstanding common stock from 2027 to 2030, subject to board discretion.","All three Class III director nominees (Taylor Schreiber, Helen Boudreau, Clay Siegall) elected with over 50M votes each.","Advisory vote on executive compensation passed with 49.85M for, 4.36M against; one-year frequency for future say-on-pay votes selected.","Ratification of KPMG as independent auditor passed with 64.8M votes for, 7,317 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94650,"accession_number":"0001628280-26-031643","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q1 net loss $14.8M; Phase 1 SL-325 enrollment complete, data Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and equivalents $90.4M as of March 31, 2026, up from $60.9M a year ago; cash runway into 2029 assuming warrant exercise.","Phase 1 trial of SL-325 (DR3 blocking antibody) enrollment complete; safety, PK, PD data expected Q2 2026.","Phase 2 trial in Crohn's disease expected to initiate Q3 2026, subject to positive Phase 1 data and regulatory alignment.","Net loss $14.8M ($0.13 per share) vs $13.7M ($0.27) in Q1 2025; R&D expenses $10.9M vs $9.9M.","Lead bispecific DR3 antibody in IND-enabling activities; target disclosure and preclinical data expected Q2 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.13,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107175,"accession_number":"0001628280-26-014987","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-03-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports FY2025 net loss $48.8M; SL-325 Ph1 data expected Q2 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2025 was $48.8M ($0.70/diluted share), vs $75.4M ($1.49) in FY2024.","Cash and investments at Dec 31, 2025 were $78.1M; after $21.4M ATM raise in Q1 2026, pro forma cash ~$94.5M.","SL-325 Phase 1 in healthy volunteers nearly complete; data expected Q2 2026, Phase 2 in Crohn's planned Q3 2026.","R&D expenses fell to $35.3M from $67.2M, driven by discontinuation of SL-172154 program.","Michael Choi, M.D., appointed VP of Clinical Development; cash runway guidance extended into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107174,"accession_number":"0001193125-26-039488","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-02-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Shattuck Labs 2026 annual meeting set for May 28; proxy deadlines revised","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting scheduled for May 28, 2026; proxy materials to be distributed later.","Stockholder proposals under Rule 14a-8 must be received by Feb 15, 2026.","Director nominations and other proposals under Bylaws must be received Jan 28–Feb 27, 2026.","Revised deadlines due to meeting being more than 30 days before prior year anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107173,"accession_number":"0001193125-26-019682","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Shattuck Labs enters $75M ATM equity distribution agreement with Leerink Partners","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Sales Agreement with Leerink Partners for at-the-market offering of up to $75M of common stock.","Shares sold at market prices; company not obligated to sell any shares.","Proceeds to fund ongoing/planned clinical trials and for working capital/general corporate purposes.","Agent commission of up to 3% of gross sales price plus reimbursement of expenses.","Registration statement on Form S-3 declared effective January 21, 2026; prospectus supplement filed January 22, 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123509,"accession_number":"0001680367-25-000056","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q3 net loss $10.1M; SL-325 Phase 1 dosing underway; $103M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["First participants dosed in Phase 1 trial of SL-325 (DR3 antagonist) in healthy volunteers; SAD/MAD enrollment expected Q2 2026.","Closed $103M private placement in August 2025; cash runway extended into 2029 assuming full warrant exercise.","Net loss $10.1M ($0.14/sh) vs $16.6M ($0.33/sh) in Q3 2024; R&D expenses down to $7.6M from $16.3M.","Appointed Dan Baker, M.D. and Mona Ashiya, Ph.D. to Board of Directors in August 2025.","Cash and equivalents $86.1M as of Sept 30, 2025; funding to support SL-325 through Phase 2 and other milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.62,"consensus_revenue_estimate":null,"consensus_revenue_actual":1000000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123508,"accession_number":"0001680367-25-000060","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K/A","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs doses first volunteers in Phase 1 trial of SL-325; closes $103M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First participants dosed in Phase 1 trial of SL-325, a DR3 antagonist antibody, in healthy volunteers.","Closed private placement of up to $103M in August 2025; cash expected to fund operations into 2029.","Net loss of $10.1M ($0.14 per share) vs $16.6M ($0.33) in Q3 2024; R&D expenses down to $7.6M.","Cash and investments at $86.1M as of Sep 30, 2025, supporting pipeline advancement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140186,"accession_number":"0001193125-25-188078","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-08-26T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Shattuck closes up to $103M private placement, appoints two new directors, cash runway into 2029","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of up to ~$103M led by OrbiMed; net proceeds to fund SL-325 through Phase 2 trials.","Pro forma cash, assuming full warrant exercise, expected to fund operations into 2029.","Appointed Dr. Daniel Baker (independent director) and Dr. Mona Ashiya (OrbiMed designee) to Board.","Directors Tyler Brous, Carrie Brownstein, Michael Lee, Kate Sasser resigned upon closing.","SL-325 (DR3 blocking antibody) IND cleared; Phase 1 trial to start this quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140185,"accession_number":"0001680367-25-000044","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss narrows to $12.5M; IND submitted for SL-325 Phase 1, $103M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $12.5M ($0.24/sh) vs $21.6M ($0.42/sh) YoY; R&D costs fell to $8.7M from $19.2M.","Cash $50.5M as of June 30; up to $103M from oversubscribed private placement led by OrbiMed to fund ops into 2029.","Submitted IND for SL-325 (DR3 blocking antibody) in July 2025; clearance expected Q3 2025; first dosing in Phase 1 expected Q3 2025.","Phase 1 trial in healthy volunteers to complete Q2 2026; funds expected to support operations into 2029."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.51,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140184,"accession_number":"0001193125-25-173010","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-08-05T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Shattuck Labs raises up to $103M in oversubscribed private placement to fund SL-325 Phase 2 trials","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial $46M gross proceeds from shares/pre-funded warrants; up to $57M additional if common warrants fully exercised.","OrbiMed led round; participation from Adage Capital, Redmile Group, Coastlands Capital, Prosight Capital, NextBio Capital.","Proceeds to fund SL-325 Phase 1 (start Q3 2025) and multiple Phase 2 trials including IBD; cash runway into 2029.","Common warrants ($1.0846 exercise) expire 30 days after public Phase 1 data announcement, expected in 2026.","Closing contingent on IND clearance for SL-325; certain investors receive board designation rights at closing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140183,"accession_number":"0001193125-25-159387","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-07-15T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shattuck Labs stockholders elect Class II directors, ratify KPMG as auditor","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Neil Gibson, George Golumbeski, and Kate Sasser elected as Class II directors with 29.6M–30.4M votes for each.","Ratification of KPMG LLP as independent auditor passed with 41.0M votes for, 5,482 against, 5,050 abstentions.","Annual Meeting held July 10, 2025; 47.9M shares entitled to vote as of May 14 record date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157829,"accession_number":"0001680367-25-000030","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-05-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q1 net loss $13.7M, cash $60.9M; SL-325 IND filing expected Q3 2025","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $13.7M ($0.27 per share) for Q1 2025 compared to $18.5M ($0.37 per share) in Q1 2024.","Cash and equivalents of $60.9M as of Mar 31, 2025, expected to fund operations into 2027.","SL-325 IND filing expected in Q3 2025; Phase 1 SAD portion first patient in Q3 2025, enrollment complete Q2 2026.","R&D expenses decreased to $9.9M from $16.3M YoY; G&A expenses decreased to $4.5M from $4.9M.","Wind-down activities for discontinued oncology programs substantially completed."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":0.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176207,"accession_number":"0001680367-25-000009","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2025-03-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q4 2024 net loss $18.7M; advances SL-325 DR3 antibody to Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Cash and investments $73.0M as of Dec 31, 2024; expected to fund operations into 2027.","Net loss Q4 2024 $18.7M ($0.37/share) vs $17.7M ($0.41) Q4 2023; FY loss $75.4M vs $87.3M.","R&D expenses $15.4M Q4; full year $67.2M down from $74.3M due to termination of SL-172154 program.","SL-325 DR3 blocking antibody on track for IND filing in Q3 2025; Phase 1 enrollment expected complete Q2 2026.","Preclinical NHP data at ECCO showed favorable safety, full receptor occupancy, no DR3 agonism."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193098,"accession_number":"0001680367-24-000050","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q3 net loss $16.7M; shifts focus to SL-325 DR3 antibody; cash runway into 2027","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $16.7M ($0.33 per share) vs $27.5M in Q3 2023; no revenue (pre-revenue stage).","Strategic pivot: discontinuing SL-172154; prioritizing first-in-class DR3 antagonist SL-325 with IND filing expected Q3 2025.","Cash and investments ~$90.1M as of Sept 30, 2024, expected to fund operations into 2027.","Substantially completed restructuring (workforce reduction) tied to SL-172154 discontinuation.","R&D expenses fell to $16.3M from $24.2M; G&A expenses dropped to $4.6M from $5.1M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.12,"consensus_revenue_estimate":null,"consensus_revenue_actual":5721000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193097,"accession_number":"0001193125-24-229480","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-10-01T23:59:59+00:00","items":["1.02","2.05","8.01","9.01"],"status":"ready","headline":"Shattuck Labs discontinues SL-172154, cuts 40% workforce, pivots to DR3 antagonist SL-325","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Discontinued SL-172154 after interim OS data showed only modest improvement vs azacitidine monotherapy in TP53m AML/HR-MDS.","Plans to focus on SL-325, a first-in-class DR3 antagonist antibody for IBD; IND filing expected Q3 2025.","Approximately 40% workforce reduction; expects restructuring charges of $1.5M-$1.75M in Q4 2024.","Cash runway extended into 2027, with $105.3M cash, cash equivalents and investments as of June 30, 2024.","Mutually terminated collaboration with Ono Pharmaceutical; no future reimbursements, milestones, or royalties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209471,"accession_number":"0001680367-24-000038","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-08-01T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs Q2 net loss $21.5M; SL-172154 shows 67% ORR in HR-MDS trial","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $21.5M ($0.42 per share) vs $21.3M ($0.50 per share) Q2 2023.","Cash and investments $105.3M as of June 30, 2024, down from $117.2M a year ago.","SL-172154 in frontline HR-MDS: 67% ORR, 58% CR/marrow CR rate; median OS not reached.","Randomized Part D enrollment initiated in frontline HR-MDS (1:1:1 vs AZA alone).","Cash runway into 2026, beyond Phase 1 trial results."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.79,"consensus_revenue_estimate":null,"consensus_revenue_actual":2724000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227538,"accession_number":"0001193125-24-161087","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Shattuck Labs reports 67% ORR in HR-MDS, 43% in TP53m AML from SL-172154 Phase 1B","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Observed 67% ORR in frontline HR-MDS patients (24 treated), with 42% complete remission rate; median survival not yet reached.","In 21 frontline TP53m AML patients, ORR 43% with 29% CR; median survival not reached; 5 patients bridged to transplant.","Manageable safety: no grade 3+ IRRs with dexamethasone premedication; no hemolytic anemia; deaths unrelated to SL-172154.","Company focusing later-stage development on HR-MDS and TP53m AML; no further PROC development due to competitive landscape.","Enrollment underway for randomized controlled HR-MDS cohort; regulatory discussions expected later this year."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227535,"accession_number":"0001193125-24-159174","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K/A","filed_at":"2024-06-11T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Shattuck Labs appoints new directors to board committees","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Kate Sasser appointed to Nominating and Corporate Governance Committee effective June 11, 2024.","Dr. Clay Siegall appointed to Compensation Committee effective June 11, 2024.","Both were previously appointed to the Board on March 4, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227537,"accession_number":"0001193125-24-158369","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-06-10T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Shattuck Labs reports 2024 annual meeting vote results; all proposals approved","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Tyler Brous elected as Class I director with 35,243,095 votes for; 130,433 withheld; 6,153,480 broker non-votes.","Carrie Brownstein, M.D. elected with 31,974,536 votes for; 3,398,585 withheld; 6,153,887 broker non-votes.","Michael Lee elected with 31,970,466 votes for; 3,402,655 withheld; 6,153,887 broker non-votes.","Ratification of KPMG LLP as independent auditor: 41,479,667 for, 19,768 against, 27,573 abstain (no broker non-votes)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227536,"accession_number":"0001680367-24-000024","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-05-02T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Q1 net loss $18.5M, cash $114.6M; expects data at EHA June 2024","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $18.5M ($0.37 per share) vs $20.7M ($0.49) in Q1 2023; R&D $16.3M, G&A $4.9M.","Cash and investments $114.6M at March 31, 2024, down from $135.5M a year ago; cash runway into 2026.","Phase 1B expansion for TP53m AML completed enrollment; randomized HR-MDS cohort expected Q2 2024; data at EHA June 2024.","Appointed Clay Siegall, Ph.D., and Kate Sasser, Ph.D. to Board of Directors effective March 1, 2024.","Entered collaboration with Ono Pharma for bifunctional fusion proteins in autoimmune/inflammatory diseases."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.37,"consensus_revenue_estimate":null,"consensus_revenue_actual":1115000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246371,"accession_number":"0001193125-24-056839","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-03-04T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Shattuck Labs appoints Dr. Clay Siegall and Dr. Kate Sasser to board of directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointments effective March 1, 2024; board now includes two new independent directors.","Dr. Siegall is CEO/Chairman of Immunome (IMNM) and former CEO/Chairman of Seagen (acquired by Pfizer).","Dr. Sasser is Chief Scientific Officer of Tempus AI and previously led translational research at Genmab and J&J.","Co. expects clinical updates for SL-172154 mid-2024 and plans late-stage/pivotal studies in multiple indications."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246370,"accession_number":"0001680367-24-000012","cik":1680367,"company_name":"Shattuck Labs, Inc.","ticker":"STTK","form_type":"8-K","filed_at":"2024-02-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Shattuck Labs reports Q4 net loss $17.7M, cash $130.6M; SL-172154 data expected mid-2024; Ono deal up to $227M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Net loss $17.7M (Q4 2023) vs $25.4M (Q4 2022); full-year $87.3M vs $101.9M; cash $130.6M at year-end.","Positive Phase 1A/B SL-172154 data in HR-MDS and TP53m AML; completed initial enrollment for expansion cohorts.","Completed Phase 1B SL-172154 + PLD trial in PROC with positive interim data; all mid-2024 updates expected.","Strategic collaboration with Ono Pharma for autoimmune targets; up to $227M in milestones plus tiered royalties.","Completed $50M public offering in Q4 2023; cash runway extended into 2026 beyond Phase 1 readouts."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":453948668.4356436,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}